Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Addiction. 2020 Aug 9;116(1):83–93. doi: 10.1111/add.15115

Table 2: Characteristics of Patients Receiving Methadone and Buprenorphine Treatment in Ukraine (N=14,176).

Characteristic Type of Opioid Agonist Treatment P-value*
Methadone
N=12,845 (91%)		 Buprenorphine
N=1,331 (9%)
Median age, years (IQR) 37 (33–43) 38 (34–44) <0.001
Sex <0.001
 Male 10,640 (91.0) 1,048 (9.0)
 Female 2205 (88.6) 283 (11.4)
Median drug injection duration, years (IQR) 17 (13–22) 19 (15–23) <0.001
Median dose, mg (IQR) 60 (35–90) 10 (6–12) NA
HIV positive <0.001
 Positive 5107 (89.4) 712 (10.6)
 Negative 7625 (91.5) 608 (8.5)
 Unknown 113 (91.1) 11 (8.9)
OAT setting type <0.001
 Narcology 6674 (85.8) 1106 (14.2)
 General hospital 4883 (99.6) 17 (0.4)
 AIDS center 863 (84.9) 154 (11.1)
 TB center 425 (88.7) 54 (11.3)

IQR: interquartile range; NA: not applicable; OAT: opioid agonist therapy.

*

P-value for Chi-Square test.